An observational study in Dialysis, Critically Ill Acute Kidney Injury and Renal Replacement Therapy for Acute Kidney Injury in ICU, sponsored by University of Alabama at Birmingham. Recruiting at 15 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by University of Alabama at Birmingham · Observational
This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:
The main aims of this study are to:
1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Critically ill patients with AKI requiring RRT in Latin American countries
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Critically ill adult patients with acute kidney injury undergoing any form of renal replacement therapy in Latin American hospitals
In-hospital mortality
The variable is coded as 1 = deceased and 0 = alive by the time of hospital discharge
Time frame: From enrollment to hospital discharge or 90 days (whichever occurs first)
ICU mortality
The variable is coded as 1 = deceased and 0 = alive by the time of ICU discharge
Time frame: From enrollment to ICU discharge or 90 days (whichever occurs first)
90-day follow-up mortality
The variable is coded as 1 = deceased and 0 = alive by the time of 90-day follow-up
Time frame: From enrollment to 90-days post-ICU admission follow-up
Length of stay in the ICU
Length of stay will be calculated as the total number of full days between admission and discharge from the ICU. A calendar day will be counted toward the total only if the duration of stay on that day is two hours or longer.
Time frame: From ICU admission to death or ICU discharge (truncated at 90 days)
Length of stay in the hospital
Length of stay will be calculated as the total number of full days between admission and discharge from the hospital. A calendar day will be counted toward the total only if the duration of stay on that day is two hours or longer.
Time frame: From hospital admission to death or hospital discharge (truncated at 90 days)
Renal function recovery at hospital discharge
Recovery will be defined as improvement in kidney function based on serum creatinine value at hospital discharge compared with baseline serum creatinine. Baseline serum creatinine will be defined as either of the following (in order of priority) 1) Average of 3 closest outpatient values 7-365 days before index hospitalization; 2) Lowest value in the inpatient setting 7-365 days before index hospitalization; 3) Lowest value in the first 30 days during index hospitalization (not during or within 48h after RRT discontinuation). Patients who have serum creatinine \<0.3 mg/dL higher than baseline at hospital discharge will be considered to have recovered renal function.
Time frame: From enrollment to hospital discharge or 90 days (whichever occurs first)
Renal function recovery at follow-up
Recovery will be defined as improvement in kidney function based of serum creatinine value at follow-up compared with baseline serum creatinine. Baseline serum creatinine will be defined as either of the following (in order to priority) 1) Average of 3 closest outpatient values 7-365 days before index hospitalization; 2) Lowest value in the inpatient setting 7-365 days before index hospitalization; 3) Lowest value in the first 30 days during index hospitalization (not during or within 48h after RRT discontinuation). Patients who have serum creatinine \<0.3 mg/dl higher than baseline at follow-up will be considered to have recovered renal function.
Time frame: From enrollment to 90-days post-ICU admission follow-up
RRT dependence at hospital discharge
Patients will be classified as RRT-dependent if they continue to require any form of RRT at discharge. Patients who no longer require RRT will be classified as RRT-independent.
Time frame: From RRT initiation to hospital discharge or 90 days (whichever occurs first)
RRT dependence at follow-up
Patients will be classified as RRT-dependent if they continue to require any form of RRT at follow-up assessment. Patients who no longer require RRT will be considered RRT-independent.
Time frame: From RRT initiation (day 0) to 90-days post-ICU admission follow-up
Anticoagulation-related complications associated with RRT
These include complications attributable to different types of anticoagulation (systemic unfractionated heparin, systemic low molecular weight heparin, regional citrate anticoagulation, other) used during RRT. Events include hemorrhage, heparin-induced thrombocytopenia (where relevant), citrate excess (where relevant), and citrate deficit (where relevant).
Time frame: RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first)
Infectious complications associated with RRT
These include infections associated with RRT. Events include catheter-related bloodstream infections, catheter insertion-site infections, and secondary peritonitis.
Time frame: RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first)
RRT-related procedural complications
Procedural or mechanical complications occurring during RRT will be identified from medical records and bedside documentation. These include catheter malfunction (e.g., kinking, disconnection, malposition, migration, catheter tip adherence to vessel wall), circuit interruptions, circuit replacements, RRT downtime (where relevant).
Time frame: RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first)
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →